欣诺基弗拉通过EGFR/PI3K/Akt/eNOS信号通路缓解高脂肪饮食引起的勃起功能障碍
Peng-Chao Gao1,2,3,4,5, Xiao-Hui Tan1,3,4,5, Man-Cheng Xia1,3,4,5
1Department of Urology, Peking University First Hospital, Beijing 100034, PR China.
Sexual medicine
|August 14, 2025
概括
欣诺基 (HINO) 可以通过调节EGFR/PI3K/Akt/eNOS通路来缓解高脂肪饮食引起的勃起功能障碍 (ED). 这种天然化合物显示出作为治疗ED管理的治疗剂的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 勃起功能障碍 (ED) 是一个具有复杂原因的全球健康问题.
- 高脂肪饮食 (HFD) 对内皮功能产生负面影响,并导致ED.
- 欣诺基 (HINO),一种天然的双类,具有与ED治疗相关的抗氧化和抗炎性质.
研究的目的:
- 为了研究HINO对HFD诱导的ED的治疗作用.
- 阐明 HINO 作用的潜在分子机制.
- 评估HINO作为一种新型治疗ED药物的潜力.
主要方法:
- 网络药理学和分子动力学模拟用于识别HINO的分子标.
- 通过使用用棕酸治疗的鼠体洞穴内皮细胞 (RCCECs) 建立了体外模型.
- 一个体内ED模型是由养雄性老鼠HFD.
主要成果:
- 生物信息学确定了表皮生长因子受体 (EGFR) 和蛋白激酶B (Akt) 作为HINO的主要点.
- 希诺治疗增强了RCCEC的扩散,抗氧化能力和氧化的产生.
- 在HFD养的老鼠中,HINO改善了ED,改善了脂质配置文件,并通过EGFR/PI3K/Akt/eNOS通路减少了氧化应激.
结论:
- HINO在治疗ED方面显示出显著的治疗潜力.
- 该研究强调了HINO调节EGFR等关键目标的能力.
- 这些发现支持对临床ED应用中HINO的进一步研究.
相关概念视频
Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
250
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
250
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
NF-κB-dependent Signaling Pathway
7.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508


